Palopegteriparatide, a new hormone replacement drug, helped 96% of adults with hypoparathyroidism stop needing calcium supplements and 100% stop needing vitamin D medications over 3.5 years, according to Gram Research analysis of a major clinical trial. The drug maintained healthy blood calcium levels in 89% of patients and improved kidney function, with most side effects being mild or moderate.
A new medication called palopegteriparatide offers hope for people with hypoparathyroidism, a rare condition where the body doesn’t make enough parathyroid hormone. According to Gram Research analysis, a major clinical trial followed 82 adults for 3.5 years and found that the drug helped 96% of patients stop needing calcium supplements and 100% stop needing vitamin D medications. The treatment also helped maintain healthy calcium levels in the blood and improved kidney function. Most side effects were mild, suggesting this could be a game-changing option for people managing this challenging condition long-term.
Key Statistics
A Phase 3 clinical trial of 82 adults with hypoparathyroidism found that 96% of patients achieved independence from therapeutic calcium doses after 3.5 years of palopegteriparatide treatment.
In the same 3.5-year trial, 100% of patients receiving palopegteriparatide discontinued active vitamin D medications while maintaining healthy blood calcium levels.
The palopegteriparatide trial showed that 89% of the 73 patients who completed 3.5 years of treatment maintained normocalcemia (healthy blood calcium levels) without additional conventional therapy.
Kidney function, measured by estimated glomerular filtration rate, improved and was preserved through 3.5 years in adults receiving palopegteriparatide for hypoparathyroidism.
The Quick Take
- What they studied: Whether a new drug called palopegteriparatide can safely replace the hormones that people with hypoparathyroidism cannot make on their own
- Who participated: 82 adults with hypoparathyroidism from 21 hospitals in North America and Europe. Most completed the full 3.5-year study period.
- Key finding: After 3.5 years, 96% of patients no longer needed calcium supplements, 100% stopped needing vitamin D medications, and 89% maintained healthy blood calcium levels without additional treatment
- What it means for you: If you have hypoparathyroidism, this drug could reduce or eliminate the need for daily calcium and vitamin D pills. However, this is a new treatment, so talk with your doctor about whether it’s right for your situation.
The Research Details
This was a Phase 3 clinical trial, which is the final stage of testing before a drug can be approved. The study had two parts: first, 82 patients received either the new drug or a placebo (fake pill) for 26 weeks without knowing which they got. Then, all patients received the actual drug for an additional 156 weeks (about 3 years). Researchers started patients on a low dose and gradually increased it to find the right amount for each person.
Throughout the study, doctors measured whether patients could stop taking calcium and vitamin D supplements, checked if their blood calcium stayed in the healthy range, and monitored their kidney function and bone health. They also asked patients how they felt and whether their quality of life improved.
This research design is important because it shows how well the drug works over a long time. The first part (with placebo) proves the drug actually works and isn’t just a placebo effect. The longer second part shows whether the benefits last and whether any problems develop after years of use. This gives doctors and patients confidence that the treatment is both safe and effective for the long haul.
This study is high-quality because it was randomized (patients were randomly assigned to groups), double-blind (neither patients nor doctors knew who got the real drug initially), and placebo-controlled (there was a comparison group). The fact that 73 out of 82 patients completed the full 3.5 years shows good follow-up. The study was published in a respected medical journal and included careful monitoring of safety and kidney function.
What the Results Show
The results were remarkably positive. By the end of 3.5 years, 70 out of 73 patients (96%) no longer needed therapeutic doses of calcium supplements. All 73 patients (100%) stopped needing active vitamin D medications. This is significant because most people with hypoparathyroidism must take these supplements daily for life.
Blood calcium levels stayed in the healthy range for 89% of patients (65 out of 73). The drug helped normalize how much calcium was being lost in urine, which is important for kidney health. Kidney function, measured by a test called eGFR, actually improved over time. Bone turnover markers, which show how active bone metabolism is, increased from baseline and then stabilized at healthy levels.
Bone mineral density, a measure of bone strength, trended toward normal values for the patients’ age and sex. Patient-reported outcomes, meaning how patients felt about their health and daily life, improved and stayed improved throughout the study. These improvements in quality of life are just as important as the medical measurements because they show the drug helps people feel better and function better in their daily lives.
Before this drug, people with hypoparathyroidism had limited options. They typically needed to take calcium and vitamin D supplements multiple times daily and monitor their blood calcium frequently. Some patients struggled to maintain healthy calcium levels despite high doses of supplements. This new drug represents a major advance because it replaces the missing hormone directly, similar to how insulin replaces missing hormone in diabetes. Previous treatments were managing symptoms, but this drug addresses the root cause.
The study included only 82 patients, which is relatively small for a major trial. All participants were from North America and Europe, so results may not apply to other populations. The study didn’t compare palopegteriparatide directly to other newer treatments for hypoparathyroidism. Some patients dropped out during the study, though most completed it. Long-term effects beyond 3.5 years remain unknown.
The Bottom Line
If you have hypoparathyroidism and struggle with managing calcium and vitamin D supplements, ask your doctor about palopegteriparatide. The evidence strongly supports its safety and effectiveness over 3.5 years. However, this is a new medication, so insurance coverage may be limited, and your doctor needs to determine if you’re a good candidate. This recommendation has high confidence based on the clinical trial results.
This research matters most for adults with hypoparathyroidism who currently take calcium and vitamin D supplements. It’s especially relevant for people who have difficulty managing their condition or experience side effects from current treatments. People with mild hypoparathyroidism that’s well-controlled with supplements may not need to switch. This treatment is not for children or pregnant women based on current evidence.
Based on the study, most patients saw benefits within the first 26 weeks (6 months). The full benefits, including improvements in kidney function and bone health, took longer to develop and were stable by 3.5 years. You should expect to work with your doctor on dose adjustments for several months before reaching your optimal dose.
Frequently Asked Questions
What is hypoparathyroidism and why is it hard to treat?
Hypoparathyroidism occurs when the parathyroid glands don’t make enough parathyroid hormone, causing low blood calcium. It’s difficult to treat because patients need frequent calcium and vitamin D supplements and constant blood monitoring to prevent dangerous calcium levels.
How does palopegteriparatide work differently than calcium and vitamin D pills?
Palopegteriparatide replaces the missing parathyroid hormone directly, addressing the root cause. Calcium and vitamin D pills only manage symptoms. The new drug allows most patients to stop or greatly reduce supplement use while maintaining healthy calcium levels naturally.
Is palopegteriparatide safe for long-term use?
The 3.5-year trial showed palopegteriparatide is safe with mostly mild-to-moderate side effects. However, longer-term safety beyond 3.5 years is still unknown. Your doctor should monitor you regularly with blood tests and kidney function checks.
Can palopegteriparatide improve bone health in hypoparathyroidism?
Yes. The trial showed bone turnover markers increased to healthy levels and bone mineral density trended toward normal values. This suggests the drug may help prevent bone problems that hypoparathyroidism can cause.
Who should consider switching to palopegteriparatide from supplements?
Adults with hypoparathyroidism who struggle managing multiple daily supplements, experience side effects, or have difficulty maintaining stable calcium levels are good candidates. Talk with your endocrinologist about whether it’s appropriate for your specific situation.
Want to Apply This Research?
- Track your weekly blood calcium levels and monthly supplement usage. Record whether you’re taking calcium and vitamin D pills, and note any days you skip doses. Monitor how you feel each day using a simple 1-10 energy and symptom scale.
- Set daily reminders for your palopegteriparatide injection at the same time each day. Use the app to log your calcium and vitamin D supplement doses (or note when you’ve stopped needing them). Schedule monthly check-ins with your doctor to review blood work and adjust doses if needed.
- Create a monthly dashboard showing your blood calcium trends, supplement usage over time, and symptom improvements. Set alerts for when lab work is due. Track the number of days per month you’re free from taking calcium or vitamin D supplements as a measure of independence from conventional therapy.
This article summarizes research findings and is not medical advice. Hypoparathyroidism is a serious medical condition requiring ongoing doctor supervision. Do not start, stop, or change any medications without consulting your healthcare provider. Palopegteriparatide may not be appropriate for everyone, and availability may be limited. Always discuss new treatment options with your endocrinologist or primary care physician to determine what’s best for your individual situation. This information is current as of the study publication date and may change as new evidence emerges.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.